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Childhood dilated cardiomyopathy (DCM) is 
characterized by a dilated left ventricle and systolic 
dysfunction, and in some patients also by right 
ventricle failure. It is a serious myocardial disease, 
usually idiopathic, but its infectious, metabolic and 
genetic aetiologies are increasingly revealed. DCM 
frequently results in heart failure and sometimes 
death. It is the most common form of 
cardiomyopathy and the most common reason for 
heart transplantation in children. 
The original article by Inas Adullsatar Saad in 
the September 2007 issue of the Libyan Journal of 
Medicine presents a study of natural history and 
predictors of prognosis in Arab children with 
idiopathic DCM [1]. Poor clinical outcome was 
found to be related to older age and 
echocardiographic findings of increased end-
diastolic volume z-score at presentation. On the 
other hand, a higher z-score value for 
interventricular septum and left ventricular 
posterior wall dimension in diastole was related to 
a favourable outcome. At short to medium follow-
up (up to 4 years), 50% of the patients improved 
and another 25% had a stationary course. Most of 
the patients who deteriorated died as heart 
transplantation was not an option. 
Because many children with DCM die early, 
emphasis has recently been placed on using 
echocardiographic and electrocardiographic 
measures to identify those who have the best 
chance of survival by early heart transplantation 
[2,3,17]. However, we should be aware of the 
technical difficulties of echocardiography in 
children with DCM and the large overlap of 
individual echocardiographic measures among the  
outcome groups. We still lack a more 
comprehensive, predictive risk algorithm to stratify 
children with DCM for death,transplant or recovery 
[3,17].  
 
Improving causal diagnosis by more intense 
evaluation 
At least one third of children with DCM have a 
known cause at the time of diagnosis, the rest are 
classified as idiopathic [4]. Increasing   the causal 
diagnostic rate is important to consider a cause-
specific treatment, to predict prognosis, and to 
estimate the recurrence risk when the cause is 
genetic. After initial viral and metabolic testing, 
early endomyocardial biopsy and molecular viral 
testing might improve the diagnostic evaluation, at 
least in older children [4]. With the extended use of 
early heart biopsy, a potential viral contribution 
and increasing diagnosis of lymphocytic 
myocarditis has been reported  [4,5]. Viral testing, 
including polymerase chain reaction (PCR), has 
predominantly shown positive findings of 
coxsackie and adenovirus [4,5]. In viral 
myocarditis, the effects of the virus on the cellular 
immune system, and the activation of viral 
proteases that cleave membrane-stabilizing 
proteins such as dystrophin, seem to be an 
important mechanism in enteroviral myocarditis 
and leading to later DCM. [4,6,7]. These findings 
raise the possibility of future specific treatment by 
vaccination, administration of cytokine and 
protease inhibitors or, in general terms, 
immunosuppressive or immunomodulating therapy 
[4,6]. Immunoglobulin, sometimes combined with 
corticosteroids, has been used as an 
immunomodulating therapy in acute fulminant 
myocarditis. This treatment is based mainly on 
case reports of favourable outcome [8]. 
An increasing number of metabolic and genetic 
causes of DCM are being revealed, especially in 
young patients. Thus, appropriate metabolic (urine 
and blood) laboratory testing, a thorough family 
history, and echocardiography of first-degree 
relatives should be considered [4] Molecular 
genetic studies, now increasingly available for 
clinical use, have shown that DCM is caused by 
defects in genes encoding cytoskeletal proteins eg 
defects in dystrophin and tafazzin. [4]. A recent 
Australian study showed that about 10% of 
paediatric DCM patients had parental 
consanguinity [5]. This finding may contribute to 
familial DCM and was probably due to frequent 
intra-family marriages in the original Australian 
population. In familial DCM with unsatisfactory 
prognosis, cardiac autoantibodies were predictive 
of disease development even in asymptomatic 
relatives [9].  
 
Management of heart failure- clinical practice 
and new treatment strategies. 
Conventional management to stabilise 
congestive heart failure in childhood DCM consists 
of digoxin, diuretics and inhibition of angiotensin 
converting enzyme (ACE). Aldosterone inhibitor 
might be added to spare electrolytes, and their 
long-term use is intended to decrease myocardial 
fibrosis [10]. In children with low ejection fraction 
on echocardiography, anticoagulation therapy 
based on clinical experience seems to be 
important for preventing mural thrombi. This group 
of severely ill young patients might also be 
managed by intravenous positive inotropic agents 
(beta-adrenergic agonists and phosphodiesterase 
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inhibitors) and the new calcium-sensitising agent, 
levosimedan [11]. Most recommendations for 
managing heart failure are based on trials on 
adults. However aetiologies and pathophysiology 
in children with heart failure might differ from those 
in adults, and therefore these young patients with 
heart failure and DCM might need different 
treatment strategies. 
Retrospective studies in DCM children indicate 
that prolonged use of beta-blockers (carvedilol and 
metoprolol) seem to improve ventricular function 
[12,13]. The results of a prospective multi-centre 
trial of carvedilol in pediatric DCM recently 
published, do not show improvement in heart 
failure, however there might be a differential effect 
of carvedilol based on ventricular morphology. 
Furthermore the trial was underpowered [14,15]. 
Mechanical circulatory support, such as left 
ventricular assist devices, even in young severely 
ill patients with DCM, is now available for short-
term cardiac support, or more prolonged use as a 
bridge to heart transplantation [16]. There have 
also been successful trials with devices in small 
groups of grown-up children with heart failure 
using implantable cardioverter defibrillators and 
both acute and long-term resynchronisation 
therapy in children with ventricular dyssynchrony 
[16 ].   
These new therapies for severely ill paediatric 
patients with DCM might improve the final outcome 
considering the limitations in use of paediatric 
heart transplantation. 
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